Company intelligence / Profile preview

Stardots

Ownership: Private
Development stage: Clinical

Overview

Stardots has developed ANLIVA™, a digital biomarker platform that enables objective symptom quantification and remote monitoring for neurological conditions such as Parkinson’s disease. The company supports clinicians with evidence-based tools to optimize diagnostics and individualized care. As of 2024, Stardots has secured multiple clinical trials in the US and other markets but does not yet have commercialized products.

Therapeutic areas: PsychiatryNeurology
Modalities: DeviceSoftware as a Medical Device (SaMD)Digital biomarker platform
Industry: Physiological Monitoring

Partnerships

Uppsala University (collaboration on AI-powered application development)Business Sweden LEAP Accelerator program support for international expansion

Beyond the preview

Go deeper on Stardots.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stardots.

Explore the full profile